197 related articles for article (PubMed ID: 36692000)
1. Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms.
Chan GKL; Maisel S; Hwang YC; Pascual BC; Wolber RRB; Vu P; Patra KC; Bouhaddou M; Kenerson HL; Lim HC; Long D; Yeung RS; Sethupathy P; Swaney DL; Krogan NJ; Turnham RE; Riehle KJ; Scott JD; Bardeesy N; Gordan JD
Elife; 2023 Jan; 12():. PubMed ID: 36692000
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
3. An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma.
Turnham RE; Smith FD; Kenerson HL; Omar MH; Golkowski M; Garcia I; Bauer R; Lau HT; Sullivan KM; Langeberg LK; Ong SE; Riehle KJ; Yeung RS; Scott JD
Elife; 2019 May; 8():. PubMed ID: 31063128
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase A regulates MYC protein through transcriptional and post-translational mechanisms in a catalytic subunit isoform-specific manner.
Padmanabhan A; Li X; Bieberich CJ
J Biol Chem; 2013 May; 288(20):14158-14169. PubMed ID: 23504319
[TBL] [Abstract][Full Text] [Related]
5. Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E(2) -induced proliferation of human umbilical cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression.
Jang MW; Yun SP; Park JH; Ryu JM; Lee JH; Han HJ
J Cell Physiol; 2012 Dec; 227(12):3756-67. PubMed ID: 22378492
[TBL] [Abstract][Full Text] [Related]
6. Drosophila insulin and target of rapamycin (TOR) pathways regulate GSK3 beta activity to control Myc stability and determine Myc expression in vivo.
Parisi F; Riccardo S; Daniel M; Saqcena M; Kundu N; Pession A; Grifoni D; Stocker H; Tabak E; Bellosta P
BMC Biol; 2011 Sep; 9():65. PubMed ID: 21951762
[TBL] [Abstract][Full Text] [Related]
7. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
8. ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.
Wu M; Zhou Y; Fei C; Chen T; Yin X; Zhang L; Ren Z
Int J Oncol; 2020 Sep; 57(3):845-857. PubMed ID: 32705157
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma.
Lu L; Han H; Tian Y; Li W; Zhang J; Feng M; Li Y
Mol Carcinog; 2015 Nov; 54(11):1467-79. PubMed ID: 25284017
[TBL] [Abstract][Full Text] [Related]
10. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.
Li Y; Takahashi M; Stork PJS
J Biol Chem; 2013 Sep; 288(38):27646-27657. PubMed ID: 23893412
[TBL] [Abstract][Full Text] [Related]
11. c-Myc protein is stabilized by fibroblast growth factor 2 and destabilized by ACTH to control cell cycle in mouse Y1 adrenocortical cells.
Lepique AP; Moraes MS; Rocha KM; Eichler CB; Hajj GN; Schwindt TT; Armelin HA
J Mol Endocrinol; 2004 Dec; 33(3):623-38. PubMed ID: 15591023
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.
Weissinger EM; Eissner G; Grammer C; Fackler S; Haefner B; Yoon LS; Lu KS; Bazarov A; Sedivy JM; Mischak H; Kolch W
Mol Cell Biol; 1997 Jun; 17(6):3229-41. PubMed ID: 9154822
[TBL] [Abstract][Full Text] [Related]
13. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
14. DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein.
An J; Yang DY; Xu QZ; Zhang SM; Huo YY; Shang ZF; Wang Y; Wu DC; Zhou PK
Mol Cancer; 2008 Apr; 7():32. PubMed ID: 18426604
[TBL] [Abstract][Full Text] [Related]
15. c-MYC activates protein kinase A (PKA) by direct transcriptional activation of the PKA catalytic subunit beta (PKA-Cbeta) gene.
Wu KJ; Mattioli M; Morse HC; Dalla-Favera R
Oncogene; 2002 Nov; 21(51):7872-82. PubMed ID: 12420224
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.
Desbois-Mouthon C; Blivet-Van Eggelpoël MJ; Beurel E; Boissan M; Delélo R; Cadoret A; Capeau J
Hepatology; 2002 Dec; 36(6):1528-36. PubMed ID: 12447879
[TBL] [Abstract][Full Text] [Related]
18. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
19. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
20. cAMP-Dependent Protein Kinase A (PKA)-Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes.
Liu Q; Nguyen E; Døskeland S; Ségal-Bendirdjian É
Mol Pharmacol; 2015 Sep; 88(3):469-76. PubMed ID: 26104548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
